Design, synthesis and biological evaluation of novel potent STAT3 inhibitors based on related heterocycle-fused naphthoquinones for cancer therapy-Reference-Cited by-同舟云学术

Design, synthesis and biological evaluation of novel potent STAT3 inhibitors based on related heterocycle-fused naphthoquinones for cancer therapy

Published:2023 Issue:1 Volume:47 Page:156-166
ISSN:1144-0546
Container-title:New Journal of Chemistry
language:en
Short-container-title:New J. Chem.

Author:

Chen Yuanguang¹,Xu Huashen¹,Chen Lu¹,Zhang Maoying¹,Yang Dexiao²,Tong Minghui²,Shi Xuan²,Liu Zhongbo³,Chen Guoliang¹^ORCID

Affiliation:

1. Key Laboratory of Structure-Based Drug Design & Discovery of Ministry of Education, School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, Shenyang, 110016, China

2. D BioOptima Co., Ltd, Suzhou, 215104, P. R. China

3. School of Pharmacy, Shenyang Pharmaceutical University, Shenyang, 110016, China

Abstract

Persistently activated signal transducer and activator of transcription 3 (STAT3) plays an important role in the development of multiple cancers, and therefore it is a potential therapeutic target for cancer treatment.

Funder

National Natural Science Foundation of China

Natural Science Foundation of Shandong Province

Taishan Industry Leading Talents

Liaoning Revitalization Talents Program

Department of Education of Liaoning Province

Publisher

Royal Society of Chemistry (RSC)

Subject

Materials Chemistry,General Chemistry,Catalysis

Link

http://pubs.rsc.org/en/content/articlepdf/2023/NJ/D2NJ05206G

Reference36 articles.

1. Noteworthy Secondary Metabolites Naphthoquinones – their Occurrence, Pharmacological Properties and Analysis

2. Red Lapacho (Tabebuia impetiginosa)—A global ethnopharmacological commodity?

3. Medicine and magic among the Maka indians of the Paraguayan Chaco

4. Pharmacopeia of qollahuaya andeans

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Small molecular inhibitors and degraders targeting STAT3 for cancer therapy: An updated review (from 2022 to 2024);Chinese Chemical Letters;2024-09